Aruna’s AB126, a therapeutic exosome, is an innovative neural anti-inflammatory and neuromodulator that naturally crosses the blood-brain-barrier. Using exosomes from neural stem cells, Aruna's AB126 has several therapeutic benefits. It reduces pro-inflammatory T-cells, increases anti-inflammatory T-cells and macrophages, protects cells from death and increases neural stem cell regeneration. This gives it enormous potential to be a powerful therapeutic that mitigates the damaging inflammatory effects of chronic neurodegenerative diseases and acute conditions like stroke and TBI while protecting and regenerating cells to aid in the recovery. Aruna is in the process of filing their first IND, anticipated Q2 2023 for treatment of ischemic stroke. Demonstrating the clinical effect of AB126 in stroke patients provides validation of ability to treat neurodegenerative diseases, a less aggressive form of neuroinflammation and cell death.
Company Type:
Privately Funded Company
Company Website:
Company HQ State:
Georgia
Company HQ Country:
United States
Year Founded:
2017
Main Therapeutic Focus:
CNS/Neurological
Lead Product in Development:
AB126
Development Phase of Primary Product:
Pre-Clinical
Number Of Unlicensed Products (For Which You Are Seeking Partners):
Multiple
Speaker
